Day: June 18, 2021

Cleantech company Dlaboratory Sweden AB (publ) has developed a generic component to its grid analytics platform, called dXport. Making data export and systems integration easy, dXport opens up the possibilities of adding an extra, data driven edge to grid operations. It has today successfully been applied to a NIS-system. Integrating different systems and tools are time efficient investments, making operations run more smoothly for companies of all kinds. It has become a fundamental part of our day-to-day activities, even in simple daily tasks, as our society has become more and more digital. Systems integration has over the last few years become increasingly important, and in technically complex operations, data export and integration are vital parts. – Although our focus, to date, has been in developing an independent solution,...

Good morning, Please find below the press release issued today. Best regards, ____________________________________________________________________ Marishka MartinsGroup Press Office Capgemini India | Mumbaiwww.capgemini.com Tel.: +91 9930835325 Email: marishka.martins@capgemini.com_____________________________ Sogeti in Sweden exclusive winner of €220 million multi-year framework agreementStockholm, Sweden, June 18, 2021 – Sogeti in Sweden, part of the Capgemini Group, has won an exclusive new Framework Agreement with the Swedish Transport Administration covering IT services for application development and management. The agreement initially runs over four years and can be extended for a further three. Following a review of its IT operations, the Swedish Transport Administration, a government authority headquartered in Borlänge, responsible...

Orphazyme A/SCompany announcement        No. 16/2021Inside informationCompany Registration No. 32266355   Copenhagen – June 18, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases, today announced it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) following its review of the new drug application for arimoclomol, a heat shock protein amplifier intended for the treatment of Niemann-Pick disease type C (NPC). The FDA issued the CRL based on needing additional qualitative and quantitative evidence to further substantiate the validity and interpretation of the 5-domain NPC Clinical Severity Scale (NPCCSS) and, in particular, the swallow domain. Further, the FDA noted in the CRL that additional...

MONTRÉAL, June 18, 2021 (GLOBE NEWSWIRE) — Nouveau Monde Graphite Inc. (“Nouveau Monde” or the “Company”) (NYSE: NMG; TSXV: NOU) today announced the pricing of its previously announced underwritten public offering (the “Offering”) of 7,000,000 of its common shares (the “Common Shares”) at a price per share of US$7.50 (the “Offering Price”) for aggregate gross proceeds of US$52,500,000. Nouveau Monde has granted the underwriters a 30-day option to purchase up to an additional 1,050,000 Common Shares at the Offering Price. The Offering is expected to close on Wednesday, June 23, 2021, subject to customary closing conditions. Evercore ISI and BMO Capital Markets are acting as joint book-running managers for the Offering. B. Riley Securities and Stifel GMP are also acting as joint book-running managers. Roth Capital Partners is acting...

This announcement contains inside information NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) — Tremor International Ltd. (“Tremor”) announced today the pricing of its initial public offering of 6,768,953 American Depositary Shares (“ADSs”), representing an aggregate of 13,537,906 ordinary shares, at a public offering price of $19.00 per ADS. Tremor has raised aggregate gross proceeds of $128.6 million, before deducting underwriting discounts and commissions. Each ADS offered represents two ordinary shares of Tremor. The ADSs are being offered in a registered public offering in the United States (the “Offering”). All ADSs to be sold in the Offering will be sold by Tremor. The underwriters of the offering will also have a 30-day option to purchase up to an additional 1,015,342 ADSs from Tremor at the initial public offering price. The...

BERLIN, June 17, 2021 (GLOBE NEWSWIRE) — atai Life Sciences B.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the pricing of its upsized initial public offering in the United States of 15,000,000 common shares at a price to the public of $15.00 per share. All common shares are being offered by atai. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by atai, are expected to be $225.0 million. In addition, atai has granted the underwriters a 30-day option to purchase up to an additional 2,250,000 common shares at the initial public offering price, less underwriting discounts and commissions. The offering is expected to close on June 22, 2021, subject to...